.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,705,518

« Back to Dashboard

Details for Patent: 5,705,518

Title: Method of activating photosensitive agents
Abstract:A method of administering photodynamic therapy begins with administering to an animal an effective amount of a photosensitizing agent which is less than about one half of the usual clinical dose for the photosensitizing agent. Then, following a post injection interval which is less about one quarter of the usual post injection interval, an effective dose of light which is less than about one half of the usual clinical dose of light used in conjunction with the photosensitizing agent is administered to the animal.
Inventor(s): Richter; Anna M. (Vancouver, CA), Waterfield; Elizabeth (Vancouver, CA), Levy; Julia G. (Vancouver, CA)
Assignee: University of British Columbia (Vancouver, CA)
Filing Date:Feb 16, 1995
Application Number:08/391,414
Claims:1. A method to destroy or impair an area of neovascularization in an animal, which animal comprises both an area of neovascularization and normal tissue, which method comprises:

(a) administering to said animal an effective amount of a photosensitizing agent;

(b) transcutaneously administering to said area of neovascularization an effective amount of light of a wavelength that matches an excitation wavelength of said photosensitizing agent,

wherein said light is administered to said area of neovascularization before said photosensitizer has permeated said normal tissue, thus substantially avoiding skin photosensitivity;

and wherein the post-injection time between step (a) and step (b) varies between about one minute and three hours.

2. The method of claim 1 wherein the effective amount of the photosensitizing agent is approximately less than one half of the clinical dose of said photosensitizing agent.

3. The method of claim 1 wherein the effective amount of light is less than about half of the clinical dose of light for activation of the photosensitizing agent in photodynamic therapy.

4. The method of claim 1 wherein the photosensitizer is selected from the group consisting of a chlorin, a bacteriochlorin, a phthalocyanine, a porphyrin, a purpurin, a merocyanine, a pheophorbide and a psoralen.

5. The method of claim 1 wherein the area of neovascularization is selected from the group consisting of a tumor, an atherosclerotic deposit, a wart, and a psoriatic lesion.

6. The method of claim 4 wherein said photosensitizer is a porphyrin.

7. The method of claim 6 wherein the porphyrin is BPD or porfimer sodium.

8. The method of claim 1 wherein the animal is mammal.

9. The method of claim 8 wherein the mammal is a human.

10. The method of claim 1 wherein the post-injection time varies between about one minute and 45 minutes.

11. A method to destroy or impair a solid tumor in an animal, which animal comprises both solid tumor and normal tissue, which method comprises:

(a) administering to said animal an effective amount of benzoporphyrin derivative-monoacid (BPD-MA); and

(b) transcutaneously administering to said tumor an effective amount of light of a wavelength that matches an excitation wavelength of said BPD-MA, wherein said light is administered to said tumor before said BPD-MA has permeated said normal tissue, thus substantially avoiding skin photosensitivity;

and wherein the post-injection time between step (a) and step (b) varies between about one minute and 45 minutes.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc